UTHR

United Therapeutics Corporation

Price

$547.97

return (12m)

24.54%

p/e

17.81

p/bv

3.65

DIVIDEND YIELD

0.00%

UTHR price

United Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment UTHR

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

9.18%

3 months

2.39%

1 year

24.54%

2 years

54.65%

5 years

188.51%

10 years

366.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals UTHR

Valuation

P/E

17.81

Sector -3.32

Industry -3.32

P/BV

3.65

Sector 1.89

Industry 1.89

P/Revenue (PSR)

7.40

Sector 2.04

Industry 2.04

EV/EBITDA

51.73

Sector -219.27

Industry -219.27

EV/EBIT

55.06

Sector -48.32

Industry -48.32

P/EBITDA

13.92

Sector -22.46

Industry -22.46

P/EBIT

14.73

Sector -29.91

Industry -29.91

P/Total Assets

3.23

Sector 1.12

Industry 1.12

P/Net Current Assets

8.76

Sector -9.48

Industry -9.48

P/Working Capital

8.12

Sector -148.59

Industry -148.59

EPS

30.77

Sector -1.78

Industry -1.78

BVPS

150.24

Sector 1.98

Industry 1.98

Efficiency

Gross Margin

86.14%

Sector 41.35%

Industry 41.35%

EBITDA Margin

51.04%

Sector -17,192.92%

Industry -17,192.92%

EBIT Margin

47.95%

Sector -4,203,320.32%

Industry -4,203,320.32%

Operating Margin

44.44%

Sector -35.47%

Industry -35.47%

Net Profit Margins

41.56%

Sector -35.90%

Industry -35.90%

Asset Turnover

0.11

Sector 0.03

Industry 0.03

Profitability

ROE

20.48%

Sector -57.36%

Industry -57.36%

ROA

18.16%

Sector -59.44%

Industry -59.44%

ROIC

29.11%

Sector -2,371.18%

Industry -2,371.18%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

5.73

Sector 2.91

Industry 2.91

Net Debt / EBITDA

-6.66

Sector -21.45

Industry -21.45

Net Debt / EBIT

-7.09

Sector -8.32

Industry -8.32

Net Debt / Equity

-0.42

Sector -33,201.77

Industry -33,201.77

Gross Debt / Equity

0.00

Sector -0.85

Industry -0.85

Equity/Assets

0.89

Sector 0.46

Industry 0.46

Liabilities/Assets

0.11

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

13.35%

Sector -

Industry -

5Y Earnings CAGR

22.47%

Sector -

Industry -

Fundamentals UTHR

DRAG THE FRAME TO SEE MORE DATA

FAIR VALUE OF United Therapeutics ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$547.97

Fair Value

$322.51

Upside

-41.14%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Assets	Price ($)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
UTHR United Therapeutics Corporation	$547.97	22.06%	0.00%	17.81	3.65	20.48%	41.56%
PFE Pfizer Inc.	$28.06	18.78%	6.23%	36.34	1.84	5.07%	6.80%
ABBV AbbVie Inc.	$276.45	23.37%	2.47%	77.50	-82.49	-106.44%	9.81%
NVO Novo Nordisk A/S	$38.39	-31.32%	4.83%	9.39	4.99	53.11%	35.32%
MRK Merck & Co. Inc.	$145.36	73.18%	2.34%	113.15	8.55	7.56%	4.77%
AZN AstraZeneca PLC	$159.16	-4.81%	2.03%	19.02	4.90	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$59.57	41.54%	4.26%	12.97	5.39	41.59%	18.87%
ZTS Zoetis Inc.	$74.29	-47.23%	2.81%	11.76	9.85	83.77%	27.69%
AMGN Amgen Inc.	$413.08	44.07%	2.41%	25.51	19.08	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$749.56	32.05%	0.49%	17.80	2.43	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$111.87	71.58%	0.00%	31.72	91.40	288.13%	24.86%
MCK McKesson Corporation	$936.38	24.39%	0.36%	24.20	-28.76	-118.84%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$509.93	21.08%	0.00%	29.37	6.39	21.76%	35.00%
CAH Cardinal Health Inc.	$237.32	52.35%	0.86%	32.46	-20.43	-62.92%	0.67%
ARGX argenx SE	$803.49	0.77%	0.00%	15.66	4.13	26.35%	25.62%
HRMY Harmony Biosciences Holdings Inc.	$40.30	51.73%	0.00%	12.88	2.34	18.14%	18.88%
BIIB Biogen Inc.	$226.46	47.00%	0.00%	40.08	1.77	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

UTHR - Historical Dividends

no dividend paid in the period.

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

ABOUT United Therapeutics

United Therapeutics Corporation

Average Investor10 user rating

4.0 (14 people)

United States

30 years

Founded: 1996

1999

Time since IPO - 27 years

920

Employees

United Therapeutics Corporation (United States) is listed on the Nasdaq and has a market capitalization of $23.34 billion, with shareholders equity totaling $6.40 billion.

The company employs approximately 920 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, United Therapeutics Corporation reported $3.15 billion in revenue, generating net income of $1.31 billion.

Key financial metrics include a P/E ratio of 17.81, a price-to-book (P/B) ratio of 3.65, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker UTHR.

Market cap

$23.34 billion

Net worth

$6.40 billion

$6,400,300,000.00

Assets

$7.22 billion

$7,220,100,000.00

Total Shares Outstanding

42.60 million

42,600,000

Average Daily Trading Volume

$753.90 Thousand

$753,895.68

Sector

Health Care

Industry

Biotechnology

UTHR

revenue by Business Segment United Therapeutics

Revenue by Region United Therapeutics

UTHR revenue and profits

Financial Results UTHR

DRAG THE FRAME TO SEE MORE DATA

UTHR cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$936.38 23,12% (12M)

P/E

24.20

0.36%

ROE

-118.84%

P/BV

-28.76

CAH - Cardinal Health

$237.32 52,87% (12M)

P/E

32.46

0.86%

ROE

-62.92%

P/BV

-20.43

ABBV - AbbVie

$276.45 23,76% (12M)

P/E

77.50

2.47%

ROE

-106.44%

P/BV

-82.49

MRK - Merck & Co.

$145.36 74,00% (12M)

P/E

113.15

2.34%

ROE

7.56%

P/BV

8.55

AZN - AstraZeneca

$159.16 --4,21% (12M)

P/E

19.02

2.03%

ROE

25.77%

P/BV

4.90

PFE - Pfizer

$28.06 21,21% (12M)

P/E

36.34

6.23%

ROE

5.07%

P/BV

1.84

BMY - Bristol-Myers Squibb

$59.57 41,94% (12M)

P/E

12.97

4.26%

ROE

41.59%

P/BV

5.39

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$936.38 23,12% (12 M)

P/L

24.20

0.36%

ROE

-118.84%

P/VP

-28.76

CAH - Cardinal Health

$237.32 52,87% (12 M)

P/L

32.46

0.86%

ROE

-62.92%

P/VP

-20.43

ABBV - AbbVie

$276.45 23,76% (12 M)

P/L

77.50

2.47%

ROE

-106.44%

P/VP

-82.49

MRK - Merck & Co.

$145.36 74,00% (12 M)

P/L

113.15

2.34%

ROE

7.56%

P/VP

8.55

AZN - AstraZeneca

$159.16 --4,21% (12 M)

P/L

19.02

2.03%

ROE

25.77%

P/VP

4.90

PFE - Pfizer

$28.06 21,21% (12 M)

P/L

36.34

6.23%

ROE

5.07%

P/VP

1.84

BMY - Bristol-Myers Squibb

$59.57 41,94% (12 M)

P/L

12.97

4.26%

ROE

41.59%

P/VP

5.39

Frequently Asked Questions

What is the price of United Therapeutics (UTHR) today?

The current price of United Therapeutics (UTHR) is $547.97. The stock began the year trading around $487.25 and is currently priced at $547.97. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does United Therapeutics (UTHR) pay dividends?

United Therapeutics (UTHR) did not pay dividends over the past year.

Is United Therapeutics (UTHR) a good investment?

United Therapeutics (UTHR) is currently trading at $547.97 with a P/E ratio of 17.81. This represents a 1,508% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 24.54%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy United Therapeutics (UTHR) stock?

You can buy United Therapeutics (UTHR) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol UTHR and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of United Therapeutics (UTHR) yield today?

Over the past month, United Therapeutics (UTHR) has returned 9.18% — 24.54% over the past year, and 188.51% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of United Therapeutics (UTHR) today at the current price of $547.97 your total investment would be $54,796.50.

Based on historical performance, the investment would have grown to approximately:

$68,243.56 after 1 year
$158,093.38 after 5 years
$255,351.69 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

UTHR

United Therapeutics Corporation

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment UTHR

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING UTHR WITH OTHER STOCK

ABOUT United Therapeutics

United Therapeutics Corporation

United States

30 years

1999

920

PROFIT X PRICE UTHR

Financial Results UTHR

UTHR cash flow

Asset, Revenue and Profit Growth - UTHR

UTHR balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

Frequently Asked Questions